病毒載體和質體DNA生產市場：按產品類型、治療應用、最終產品和地區分類

Viral Vectors And Plasmid DNA Manufacturing Market, By Product Type, By Therapeutic Application, By End Product, By Geography

出版日期: 2026年04月10日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

病毒載體和質體DNA生產市場預計在2026年達到17.986億美元，預計2033年將達到75.711億美元。預計從2026年到2033年，該市場將以23%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	17.986億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	23.00%	2033年市場規模預測：	75.711億美元

病毒載體可用於將遺傳物質導入目標細胞，因此廣泛應用於多種治療領域。病毒載體在針對結核分枝桿菌、惡性瘧疾原蟲和愛滋病毒等病原體以及絲狀病毒等多種生物威脅的疫苗研發方面具有巨大潛力。質體DNA（pDNA）因其在基因疫苗和基因治療臨床研究應用方面的潛力而備受關注。作為一種新型生物技術產品，pDNA在DNA疫苗和基因治療領域的效用日益凸顯。除了直接用於治療外，pDNA還廣泛用於間接應用，例如作為瞬時轉染的原料，用於構建瞬時蛋白和病毒載體。此外，pDNA也可用作主模板產品，支援新型和在研生物製藥產品及製程（例如細胞療法）的生產。

市場動態

預計新型基因療法監管核准的增加將推動基因治療領域的成長。例如，2017年9月，GeneOne Life Science, Inc. 的在臨床實驗疫苗 GLS-5300 針對中東呼吸症候群冠狀病毒 (MERS-CoV) 的 I/IIa 期臨床實驗試驗申請獲得韓國食品藥品安全部 (KMFDS) 的批准。此外，2019年5月，AveXis Inc. 的 Zolgensma（onasemnogene abeparvovec-xioi）獲得美國食品藥物管理局(FDA) 的核准，該藥物是腺結合病毒載體的基因療法，用於治療兩歲以下兒童的脊髓性肌肉萎縮症 (SMA )。

本研究的關鍵特徵

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數創建了全球病毒載體和質體DNA製造市場主要公司的概況：公司概況、財務業績、產品系列、市場地位、分銷策略、主要發展、策略和未來計劃。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
全球病毒載體和質體DNA生產市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球病毒載體和質體DNA製造市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 中非
- 北非

第8章競爭情勢

熱圖分析
市佔率分析
- Lonza Group AG
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION BIoTech GmbH
- FUJIFILM Diosynth BIoTechnologies USA, Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics

第9章

參考
調查方法

簡介目錄

Product Code: CMI962

Viral Vectors And Plasmid DNA Manufacturing Market is estimated to be valued at USD 1,798.6 Mn in 2026 and is expected to reach USD 7,571.1 Mn by 2033, growing at a compound annual growth rate (CAGR) of 23% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,798.6 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	23.00%	2033 Value Projection:	USD 7,571.1 Mn

Viral vectors aids in transferring genetic material into target cells and therefore, used in various therapeutic areas. Viral vectors can be significantly used in vaccines development against pathogens such as Mycobacterium tuberculosis, Plasmodium falciparum, HIV, and various bio-threat targets such as filoviruses. Plasmid DNA (pDNA) is gaining traction for clinical research applications in genetic vaccination and gene therapy. It is becoming increasingly useful as novel biotechnology product for DNA vaccines and gene medicines. It can be directly used as a therapeutic agent and indirectly used for various applications such as a starting material for transient transfection to produce transient proteins and viral vector constructs. Furthermore, pDNA is used as a master-template product to support production of new and developing biopharmaceutical products and processes such as cell therapies.

Market Dynamics

Increasing approvals by regulatory authorities for novel gene therapies is expected to drive growth of the gene therapy segment. For instance, in September 2017, GeneOne Life Science, Inc., received approval from the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational New Drug application for a Phase I/IIa study of its investigational vaccine, GLS-5300, against the Middle East Respiratory Syndrome coronavirus (MERSCoV). Moreover, in May 2019, AveXis Inc. received the U.S. Food and Drug Administration approval for its Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy for the treatment of pinal muscular atrophy (SMA) in children less than two years old.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global viral vector and plasmid DNA manufacturing market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Lonza Group AG, FinVector Vision Therapies, Cobra Biologics and Pharmaceutical Services, Sigma-Aldrich Co. LLC, VGXI, Inc., VIROVEK, SIRION Biotech GmbH, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Cell and Gene Therapy Catapult, Brammer Bio, and MassBiologics.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global viral vector and plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA manufacturing market

Market Segmentation

By Product Type
- Viral Vector
- Retroviral Vectors
- Adenoviral Vectors
- Lentiviral Vectors
- Adeno-associated Viral Vectors
- Others
- Plasma DNA
- Non-viral DNA Vectors
By Therapeutic Application
- Cancer
- Inherited Disorders
- Vitrectomy Surgery Devices
- Infectious Diseases
- Others
By End Product
- DNA Vaccines
- Gene Therapy
- Immunotherapy
- Others
By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- Lonza Group AG
- FinVector Vision Therapies
- Cobra Biologics and Pharmaceutical Services
- Sigma-Aldrich Co. LLC
- VGXI, Inc.
- VIROVEK
- SIRION Biotech GmbH
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Sanofi
- Cell and Gene Therapy Catapult
- Brammer Bio
- MassBiologics

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Therapeutic Application
- Market Snippet, By End Product
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis of DROs
Comparative Analysis of Different Types of Viral Systems
Collaborations, Partnerships, And Agreements
Pipeline Analysis
New Product Launches
Investment Opportunities
Regulatory Scenario
Strategies For Product Development and Application Pathways
Brand Analysis
Cell & Gene Therapy Manufacturing Capacities Globally
Porter's Analysis

4. Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Viral Vector
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
  - Retroviral Vectors
  - Adenoviral Vectors
  - Lentiviral Vectors
  - Adeno-associated Viral Vectors
  - Others
Plasma DNA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Non-Viral DNA Vectors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

5. Global Viral Vector and Plasmid DNA Manufacturing Market, By Therapeutic Application, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Inherited Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

6. Global Viral Vector and Plasmid DNA Manufacturing Market, By End Product, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
DNA Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Mn)

7. Global Viral Vector and Plasmid DNA Manufacturing Market, By Region, 2021 - 2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2027
North America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Therapeutic Application, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By End Product, 2021 - 2033, (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Mn)
  - South Africa
  - Central Africa
  - North Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- Lonza Group AG
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- FinVector Vision Therapies
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Cobra Biologics and Pharmaceutical Services
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sigma-Aldrich Co. LLC
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- VGXI, Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- VIROVEK
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- SIRION Biotech GmbH
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Sanofi
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Cell and Gene Therapy Catapult
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Brammer Bio
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- MassBiologics
  - Company Overview
  - Product Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
  - Analyst Views